Schneyer Mark C. sold $69K of ACAD
Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER) sold 3,321 shares of ACADIA PHARMACEUTICALS INC (ACAD) at $20.88 on 2026-10-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The sale could trigger short-term price pressure but is unlikely to affect long-term valuation.
Market read
Insider sale is a primary disclosure; relevance is modest due to small transaction size.
What to watch
No change in company fundamentals; sale size is small relative to market cap.
Background
Form 4 filing provides the first public disclosure of the CFO's share sale.
Ticker impact
SEC Form 4 shows CFO Mark C. Schneyer sold 3,321 shares for $69,342, reducing his stake to 71,322 shares.
likely pressure as the market prices in the insider sale
CFO sale via 10b5-1 plan, modest size but could prompt short-term sell-off.
Market effects
Minimal impact on pharma sector; typical insider sale.
None
None
Counterpoint
Sale may be routine under 10b5-1, not indicative of company outlook.
Key entities
- CompanyAcadia Pharmaceuticals Inc.
Biopharmaceutical company developing CNS drugs.
- ExecutiveMark C. Schneyer
Executive Vice President and Chief Financial Officer of Acadia.
